Welcome to our dedicated page for Dbv Technologies S A news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on Dbv Technologies S A stock.
The DBV Technologies S.A. (DBVT) news page on Stock Titan aggregates company announcements, regulatory disclosures, and clinical development updates for this clinical-stage biopharmaceutical issuer. DBV Technologies focuses on food allergies and other immunologic conditions with significant unmet medical need, using its proprietary Viaskin patch technology and epicutaneous immunotherapy (EPIT) platform.
Investors and followers of DBV Technologies can use this news feed to review company-issued press releases and market announcements. Recent communications from DBV Technologies have covered topics such as progress in its Viaskin Peanut clinical program in peanut-allergic toddlers and children, including the Phase 3 VITESSE trial in children aged 4 to 7 years. The company has reported that VITESSE met its primary endpoint and that safety results were consistent with the existing Viaskin Peanut clinical program, positioning this trial as a key milestone in its development strategy.
In addition to clinical data updates, DBV Technologies news items include information on supplemental safety studies in toddlers, participation in healthcare and investor conferences, and changes in leadership and board composition. The company also releases regulated information related to its Euronext Paris listing, such as monthly disclosures of total shares and voting rights and reports on its liquidity contract.
Regulatory filings summarized in press releases, including U.S. SEC Form 8-K reports, provide insight into financial results, equity financing arrangements, and other corporate events. By following DBV Technologies news, readers can track developments in the Viaskin platform, food allergy programs, and the company’s dual listing on Euronext Paris and the Nasdaq Capital Market.
The monthly report as of March 31, 2022, reveals that DBVT has a total of 55,095,537 shares outstanding. The total number of voting rights attached to these shares is 55,095,537, with a net total of 54,951,036 voting rights. This net total accounts for shares without voting rights. The report is compliant with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers and is intended for shareholders and market observers.
DBV Technologies will present at Oppenheimer’s 32nd Annual Healthcare Conference on March 17, 2022, at 10:00 a.m. ET. Dr. Pharis Mohideen, the Chief Medical Officer, is set to deliver the presentation. Investors can access the webcast on the company's website, with a replay available for about 90 days post-event. DBV Technologies focuses on developing Viaskin™, an innovative technology platform for immunotherapy, particularly aimed at food allergies, with ongoing trials for Viaskin Peanut.
DBVT announced its monthly update as of February 28, 2022, regarding the total number of shares and voting rights. The company reported a total of 55,095,762 shares, with a total gross of 55,095,762 voting rights. After accounting for shares without voting rights, the total net voting rights stood at 54,919,952. This information is in compliance with the General Regulations of the Autorité des Marchés Financiers.
DBV Technologies announced the filing of its 2021 Annual Report on Form 10-K with the SEC and its 2021 Universal Registration Document with the French AMF. Both documents are accessible on the company's investor website and the respective regulatory authority sites. DBV Technologies is focused on developing the Viaskin™ platform for food allergies using epicutaneous immunotherapy, with ongoing trials for Viaskin Peanut. The company operates globally from Montrouge, France, and Summit, NJ, and its shares are listed on Euronext and Nasdaq under the ticker DBVT.
DBV Technologies reported its 2021 financial results, revealing a net loss of $97.8 million, down from $159.6 million in 2020. The company's cash and cash equivalents decreased to $77.3 million from $196.4 million in 2020. Operating income fell to $5.7 million, primarily due to reduced revenue from a collaboration with Nestlé. However, DBV extended its cash runway into Q1 2023 through cost containment measures. The pivotal protocol for the modified Viaskin Peanut patch is complete and ready for FDA submission, highlighting ongoing discussions with the FDA aimed at advancing its research and development efforts.
DBV Technologies will report its full year 2021 financial results on March 3, 2022. The company, based in Montrouge, France, is focused on developing the Viaskin platform for immunotherapy, specifically for food allergies. A conference call will be held at 5:00 p.m. ET to discuss the financial outcomes and provide corporate updates. The call can be accessed via specified teleconferencing numbers and a live audio webcast will be available on their website.
DBV Technologies (DBVT) will participate in the AAAAI 2022 Congress from February 24-28, 2022. They will present two scientific posters: one on allergy specialty care effects on healthcare utilization in children with peanut allergies and another on pooled safety data from Phase 3 trials of their Viaskin Peanut treatment. Viaskin Peanut aims to reduce allergic reactions in children aged 4-11. The presentations will be available on-demand for registered attendees and later on DBV's website.
DBV Technologies announced that CEO Daniel Tassé will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18 at 8:40 am ET. This event will be hosted in a virtual format, allowing interested parties to access the webcast through the Investors & Media section of the Company’s website. A replay will be available after the event.
DBV Technologies, based in Montrouge, France, focuses on developing Viaskin™, a proprietary technology for food allergy treatment. The Company's shares trade under the ticker DBVT on Nasdaq.
DBVT released its monthly report on voting rights and share count as of January 31, 2022. The total number of shares stood at 55,095,762, with the total gross of voting rights also at 55,095,762. The net voting rights, after accounting for shares without voting rights, totaled 54,925,155. This information ensures transparency for investors and complies with regulations set by the Autorité des Marchés Financiers.
DBV Technologies has published its Half-Year Report on the liquidity contract with ODDO BHF as of December 31, 2021.
The liquidity account contained 153,631 shares worth €175,542.33, compared to 24,313 shares and €682,454.94 at the contract's inception in July 2018. In 2021's second half, 1,206 shares were purchased and 1,065 sold, totaling 455,657 shares bought for €3,256,011.54 and 379,901 sold for €2,951,075.39. DBV is advancing Viaskin™, a non-invasive immunotherapy platform targeting food allergies.